PUL-042

DRUG2 trials

Sponsors

Pulmotect, Inc.

Conditions

Hematologic DiseasesHematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)Stem Cell Transplants

Phase 1

A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients

WithdrawnNCT03097796

Pulmotect, Inc.Hematologic Diseases, Stem Cell Transplants

Start: 2024-12-31End: 2026-05-31Updated: 2023-04-27

Phase 2

PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)

RecruitingNCT06665100

Pulmotect, Inc.Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)

Start: 2025-06-27End: 2027-05-01Target: 100Updated: 2026-08-04